Literature DB >> 25655068

Inflammation-Induced IL-6 Functions as a Natural Brake on Macrophages and Limits GN.

Michael Luig1, Malte A Kluger1, Boeren Goerke1, Matthias Meyer1, Anna Nosko1, Isabell Yan2, Jürgen Scheller3, Hans-Willi Mittrücker2, Stefan Rose-John4, Rolf A K Stahl1, Ulf Panzer1, Oliver M Steinmetz5.   

Abstract

IL-6 can mediate proinflammatory effects, and IL-6 receptor (IL-6R) blockade as a treatment for inflammatory diseases has entered clinical practice. However, opposing effects of IL-6 have been observed in models of GN. Although IL-6 is proinflammatory in murine lupus nephritis, protective effects have been observed for IL-6 in the nephrotoxic nephritis (NTN) model of acute crescentic GN. In light of the potential dangers of IL-6-directed treatment, we studied the mechanisms underlying the contradictory findings in GN. IL-6 can signal through the membrane-bound IL-6R, which is expressed only on hepatocytes and certain leukocytes (classic), or through the soluble IL-6R, which binds the ubiquitously expressed gp130 (alternative). Preemptive treatment of mice with anti-IL-6R or anti-IL-6 worsened NTN, whereas selective blockade of alternative IL-6 signaling by the fusion protein sgp130Fc did not. FACS analysis of mouse spleen cells revealed proinflammatory macrophages express the highest levels of IL-6Rα, and in vitro treatment with IL-6 blocked macrophage proliferation. Furthermore, proinflammatory macrophages were expanded during inflammation in IL-6(-/-) mice. Late application of anti-IL-6 after establishment of adaptive nephritogenic immunity was sufficient to aggravate NTN within 2.5 days, a period when macrophages are active. Finally, NTN was aggravated in mice with macrophage-specific impairment of IL-6 classic signaling, coincident with enhanced macrophage proliferation and accumulation in the kidney. Our data thus reveal a novel mechanism in which IL-6-mediated dampening of macrophage activation protects tissues from overshooting immune responses. This finding has important implications for potential IL-6-directed therapies and supports the careful choice of recipient patients and timing.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  GN; cytokines; immunology; pathology

Mesh:

Substances:

Year:  2015        PMID: 25655068      PMCID: PMC4483592          DOI: 10.1681/ASN.2014060620

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  62 in total

1.  IL-6 is required for the development of Th1 cell-mediated murine colitis.

Authors:  M Yamamoto; K Yoshizaki; T Kishimoto; H Ito
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cells.

Authors:  R Clutterbuck; R Powles; J Millar; D Catovsky
Journal:  Exp Hematol       Date:  2000-10       Impact factor: 3.084

3.  Characterization of anti-mouse interleukin-6 receptor antibody.

Authors:  Makoto Okazaki; Yoshiki Yamada; Norihiro Nishimoto; Kazuyuki Yoshizaki; Masahiko Mihara
Journal:  Immunol Lett       Date:  2002-12-03       Impact factor: 3.685

4.  Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis.

Authors:  Yusuke Matsuo; Fumitaka Mizoguchi; Hitoshi Kohsaka; Eisaku Ito; Yoshinobu Eishi; Nobuyuki Miyasaka
Journal:  Rheumatology (Oxford)       Date:  2013-01-15       Impact factor: 7.580

5.  Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis.

Authors:  Malte A Kluger; Gunther Zahner; Hans-Joachim Paust; Melanie Schaper; Tim Magnus; Ulf Panzer; Rolf A K Stahl
Journal:  Kidney Int       Date:  2013-01-23       Impact factor: 10.612

6.  Stat3 programs Th17-specific regulatory T cells to control GN.

Authors:  Malte A Kluger; Michael Luig; Claudia Wegscheid; Boeren Goerke; Hans-Joachim Paust; Silke R Brix; Isabell Yan; Hans-Willi Mittrücker; Beate Hagl; Ellen D Renner; Gisa Tiegs; Thorsten Wiech; Rolf A K Stahl; Ulf Panzer; Oliver M Steinmetz
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

Review 7.  A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.

Authors:  Toshio Tanaka; Masashi Narazaki; Atsushi Ogata; Tadamitsu Kishimoto
Journal:  Semin Immunol       Date:  2014-03-01       Impact factor: 11.130

8.  Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis.

Authors:  Takashi Iijima; Tatsuya Suwabe; Keiichi Sumida; Noriko Hayami; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Junichi Hoshino; Naoki Sawa; Kenmei Takaichi; Kenichi Oohashi; Takeshi Fujii; Yoshifumi Ubara
Journal:  Mod Rheumatol       Date:  2014-02-18       Impact factor: 3.023

Review 9.  Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Authors:  Monika M Schoels; Désirée van der Heijde; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Miho M Murikama; Norihiro Nishimoto; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2012-11-10       Impact factor: 19.103

10.  Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin.

Authors:  Jan Mauer; Bhagirath Chaurasia; Julia Goldau; Merly C Vogt; Johan Ruud; Khoa D Nguyen; Sebastian Theurich; A Christine Hausen; Joel Schmitz; Hella S Brönneke; Emma Estevez; Tamara L Allen; Andrea Mesaros; Linda Partridge; Mark A Febbraio; Ajay Chawla; F Thomas Wunderlich; Jens C Brüning
Journal:  Nat Immunol       Date:  2014-03-30       Impact factor: 25.606

View more
  32 in total

Review 1.  Key metalloproteinase-mediated pathways in the kidney.

Authors:  Tammo Ostendorf; Andreas Ludwig; Justyna Wozniak; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2021-04-20       Impact factor: 28.314

2.  Knockout of the neonatal Fc receptor in cultured podocytes alters IL-6 signaling and the actin cytoskeleton.

Authors:  Pantipa Tonsawan; James Dylewski; Linda Lewis; Judith Blaine
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-25       Impact factor: 4.249

3.  IL-6 Trans-Signaling Drives Murine Crescentic GN.

Authors:  Gerald S Braun; Yoshikuni Nagayama; Yuichi Maruta; Felix Heymann; Claudia R van Roeyen; Barbara M Klinkhammer; Peter Boor; Luigi Villa; David J Salant; Ute Raffetseder; Stefan Rose-John; Tammo Ostendorf; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2015-06-03       Impact factor: 10.121

4.  The Janus Faces of IL-6 in GN.

Authors:  Alan D Salama; Mark A Little
Journal:  J Am Soc Nephrol       Date:  2015-02-05       Impact factor: 10.121

Review 5.  Interleukin-6 Family Cytokines.

Authors:  Stefan Rose-John
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-02-01       Impact factor: 10.005

6.  iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling.

Authors:  Xiaoping Qing; Yurii Chinenov; Patricia Redecha; Michael Madaio; Joris Jth Roelofs; Gregory Farber; Priya D Issuree; Laura Donlin; David R Mcllwain; Tak W Mak; Carl P Blobel; Jane E Salmon
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

7.  RORγt expression in Tregs promotes systemic lupus erythematosus via IL-17 secretion, alteration of Treg phenotype and suppression of Th2 responses.

Authors:  M A Kluger; A Nosko; T Ramcke; B Goerke; M C Meyer; C Wegscheid; M Luig; G Tiegs; R A K Stahl; O M Steinmetz
Journal:  Clin Exp Immunol       Date:  2017-01-05       Impact factor: 4.330

8.  ADAM17 substrate release in proximal tubule drives kidney fibrosis.

Authors:  Eirini Kefaloyianni; Muthu Lakshmi Muthu; Jakob Kaeppler; Xiaoming Sun; Venkata Sabbisetti; Athena Chalaris; Stefan Rose-John; Eitan Wong; Irit Sagi; Sushrut S Waikar; Helmut Rennke; Benjamin D Humphreys; Joseph V Bonventre; Andreas Herrlich
Journal:  JCI Insight       Date:  2016-08-18

Review 9.  The Changing Landscape of Renal Inflammation.

Authors:  Thomas Ernandez; Tanya Norton Mayadas
Journal:  Trends Mol Med       Date:  2016-01-07       Impact factor: 11.951

10.  T-Bet Enhances Regulatory T Cell Fitness and Directs Control of Th1 Responses in Crescentic GN.

Authors:  Anna Nosko; Malte A Kluger; Paul Diefenhardt; Simon Melderis; Claudia Wegscheid; Gisa Tiegs; Rolf A K Stahl; Ulf Panzer; Oliver M Steinmetz
Journal:  J Am Soc Nephrol       Date:  2016-06-13       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.